Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Exclusion Criteria

• •1. Active brain metastases
• •2. Thromboembolic events \< 6 months prior to study
• •3. Patients with a recent history (within 5 years) of another malignancy.
• •4. Investigational or any antitumor treatment with a maximum of 4 half-lives or administered 30 days prior to the initial administration of REGN1400
• •5. Patients who are pregnant or nursing
• •6. Prior treatment with ErbB3 inhibitors